Peter Tontonoz, Dr. Bruce Blumberg, Xufeng Chen, Akio Kruoda, and Dr. Gang Pei for plasmids, and Sofia Loera for conducting the immunohistochemical staining

in the Anatomic Pathology Core Facility of City of Hope. Additional Supporting Information may be found in the online version of this article. “
“Pruritus is a seriously disabling symptom accompanying many cholestatic liver disorders. Recent experimental evidence implicated the lysophospholipase, autotaxin (ATX), and its product, lysophosphatidic acid (LPA), as potential mediators selleck inhibitor of cholestatic pruritus. In this study, we highlight that increased serum ATX levels are specific for pruritus of cholestasis, but not pruritus of uremia, Hodgkin’s disease, or atopic dermatitis. Proteasome inhibition Treatment of patients with cholestasis with the bile salt sequestrant, colesevelam, but not placebo, effectively reduced total serum bile salts and fibroblast growth factor 19 levels, but only marginally altered pruritus intensity and ATX activity. Rifampicin (RMP) significantly reduced itch intensity and ATX activity in patients with pruritus not responding

to bile salt sequestrants. In vitro, RMP inhibited ATX expression in human HepG2 hepatoma cells and hepatoma cells overexpressing the pregnane X receptor (PXR), but not in hepatoma cells in which PXR was knocked down. Treatment of severe, refractory pruritus by the molecular adsorbents recirculation system or nasobiliary drainage improved itch intensity, which, again, correlated with the reduction of ATX levels. Upon reoccurrence of pruritus,

ATX activity returned to pretreatment values. Conclusion: Serum ATX activity is specifically increased in patients with cholestatic, but not other forms of, systemic pruritus and 上海皓元医药股份有限公司 closely correlates with the effectiveness of therapeutic interventions. The beneficial antipruritic action of RMP may be explained, at least partly, by the PXR-dependent transcriptional inhibition of ATX expression. Thus, ATX likely represents a novel therapeutic target for pruritus of cholestasis. (HEPATOLOGY 2012) (See Editorial on Page 1194) Chronic pruritus can be a seriously debilitating symptom accompanying various cutaneous and systemic disorders.1 It represents one of the most prominent clinical features in numerous liver disorders, such as primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), cholangiocarcinoma (CCC), inherited forms of cholestasis, and intrahepatic cholestasis of pregnancy.2 This form of itching is designated cholestatic pruritus because impaired bile flow is a common denominator in these disorders.3 The molecular mechanisms involved in the pathogenesis of cholestatic pruritus remain enigmatic, and treatment of these patients often represents a clinical challenge because of limited therapeutic options.